Inventiva S.A. (EPA:IVA)
France · Delayed Price · Currency is EUR | Market Cap | 423.02M |
| Revenue (ttm) | 16.97M |
| Net Income (ttm) | -311.07M |
| Shares Out | 139.15M |
| EPS (ttm) | -3.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 290,578 |
| Average Volume | 506,201 |
| Open | 3.150 |
| Previous Close | 3.105 |
| Day's Range | 3.020 - 3.250 |
| 52-Week Range | 2.000 - 5.550 |
| Beta | 0.75 |
| RSI | 26.25 |
| Earnings Date | Nov 10, 2025 |
About Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-β, a pre-clinical program for th... [Read more]
Financial Performance
In 2024, Inventiva's revenue was 14.09 million, a decrease of -38.24% compared to the previous year's 22.82 million. Losses were -184.21 million, 66.8% more than in 2023.
Financial StatementsNews
Inventiva Announces the Implementation of a New ATM Program
Daix (France), New York City (New York, United States), October 14, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focuse...
Inventiva (IVA) Gets Boosted Price Target from HC Wainwright & Co. | IVA Stock News
Inventiva (IVA) Gets Boosted Price Target from HC Wainwright & Co. | IVA Stock News
Inventiva S.A. (IVA) Analyst/Investor Day - Slideshow
Inventiva S.A. (IVA) Analyst/Investor Day Transcript
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025
Daix (France), New York City (New York, United States), October 7, 2025 - Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused...
Inventiva Names Andrew Obenshain CEO
(RTTNews) - Inventiva S.A. (IVA), a clinical-stage biopharmaceutical company, announced on Wednesday that it has appointed Andrew Obenshain as Chief Executive Officer.
Inventiva Appoints Andrew Obenshain as Chief Executive Officer
Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused ...
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday.
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1...
Earnings Scheduled For September 29, 2025
Companies Reporting Before The Bell • Inventiva (NASDAQ: IVA) is projected to report quarterly loss at $0.41 per share on revenue of $5.31 million. • Uxin (NASDAQ: UXIN) is estimated to report earni...
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update
Daix (France), New York City (New York, United States), September 29, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focus...
Top Wall Street Forecasters Revamp Inventiva Expectations Ahead Of H1 Earnings
Inventiva S.A. (NASDAQ: IVA) will release earnings results for the first half of the year, after the closing bell on Monday, Sept.
Top Wall Street Forecasters Revamp Inventiva Expectations Ahead Of H1 Earnings
Inventiva S.A. (NASDAQ: IVA) will release earnings results for the first half of the year, after the closing bell on Monday, Sept. 29 . Analysts expect the Daix, France-based company to report H1 los...
Preview: Inventiva's Earnings
Inventiva (NASDAQ: IVA) is gearing up to announce its quarterly earnings on Monday, 2025-09-29. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...
Here's Why Inventiva (IVA) Is a Great 'Buy the Bottom' Stock Now
Inventiva (IVA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall ...
Costco Wholesale, Concentrix And 3 Stocks To Watch Heading Into Friday
With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows: Heritage Financial Corp (NASDAQ: HFWA) announced plans to acquire O...
Insights into Inventiva's Upcoming Earnings
Inventiva (NASDAQ: IVA) is set to give its latest quarterly earnings report on Friday, 2025-09-26. Here's what investors need to know before the announcement. Analysts estimate that Inventiva will re...
Inventiva to Host Analyst and Investor Event on October 8, 2025
Daix (France), New York City (New York, United States), September 24, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focus...
Inventiva (IVA) Positioned as Prime Acquisition Target
Inventiva (IVA) Positioned as Prime Acquisition Target
Inventiva to Participate in Upcoming September Investor Conferences
Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focuse...
Today's Analyst Rating: Inventiva (IVA) Receives 'Buy' Rating from HC Wainwright & Co. ...
Today's Analyst Rating: Inventiva (IVA) Receives 'Buy' Rating from HC Wainwright & Co. | IVA Stock News
Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Guggenhei...
Inventiva surges as Piper Sandler issues bullish view citing lead asset
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused ...
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the ...